CR1 and the "vanishing amyloid" hypothesis of Alzheimer's disease.
作者信息
Gandy Sam, Haroutunian Vahram, DeKosky Steven T, Sano Mary, Schadt Eric E
机构信息
Department of Psychiatry and Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
出版信息
Biol Psychiatry. 2013 Mar 1;73(5):393-5. doi: 10.1016/j.biopsych.2013.01.013.
Abstract
摘要
相似文献
1
CR1 and the "vanishing amyloid" hypothesis of Alzheimer's disease.
Biol Psychiatry. 2013 Mar 1;73(5):393-5. doi: 10.1016/j.biopsych.2013.01.013.
2
Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype.
Biol Psychiatry. 2013 Mar 1;73(5):422-8. doi: 10.1016/j.biopsych.2012.08.015. Epub 2012 Sep 27.
3
Alzheimer's disease beyond APOE.
Nat Genet. 2009 Oct;41(10):1047-8. doi: 10.1038/ng1009-1047.
4
Genetics of Alzheimer's disease: new evidences for an old hypothesis?
Curr Opin Genet Dev. 2011 Jun;21(3):295-301. doi: 10.1016/j.gde.2011.02.002. Epub 2011 Mar 1.
5
Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1.
Alzheimers Dement. 2018 Nov;14(11):1438-1449. doi: 10.1016/j.jalz.2018.04.003. Epub 2018 May 21.
6
CR1 in Alzheimer's disease.
Mol Neurobiol. 2015 Apr;51(2):753-65. doi: 10.1007/s12035-014-8723-8. Epub 2014 May 4.
7
Genetic variation at CR1 increases risk of cerebral amyloid angiopathy.
Neurology. 2012 Jan 31;78(5):334-41. doi: 10.1212/WNL.0b013e3182452b40. Epub 2012 Jan 18.
8
Effect of CR1 Genetic Variants on Cerebrospinal Fluid and Neuroimaging Biomarkers in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Cohorts.
Mol Neurobiol. 2017 Jan;54(1):551-562. doi: 10.1007/s12035-015-9638-8. Epub 2016 Jan 7.
9
CR1, ABCA7, and APOE genes affect the features of cognitive impairment in Alzheimer's disease.
J Neurol Sci. 2014 Apr 15;339(1-2):91-6. doi: 10.1016/j.jns.2014.01.029. Epub 2014 Jan 31.
10
APP, APOE, complement receptor 1, clusterin and PICALM and their involvement in the herpes simplex life cycle.
Neurosci Lett. 2010 Oct 11;483(2):96-100. doi: 10.1016/j.neulet.2010.07.066. Epub 2010 Jul 30.
引用本文的文献
1
The Alzheimer's disease-associated complement receptor 1 variant confers risk by impacting glial phagocytosis.
Alzheimers Dement. 2025 Jul;21(7):e70458. doi: 10.1002/alz.70458.
2
Complement receptor 1 is expressed on brain cells and in the human brain.
Glia. 2023 Jun;71(6):1522-1535. doi: 10.1002/glia.24355. Epub 2023 Feb 24.
3
Alzheimer mutant speeds APP transport.
J Exp Med. 2021 Jun 7;218(6). doi: 10.1084/jem.20210511. Epub 2021 May 14.
4
Complement Activation in the Central Nervous System: A Biophysical Model for Immune Dysregulation in the Disease State.
Front Mol Neurosci. 2021 Mar 4;14:620090. doi: 10.3389/fnmol.2021.620090. eCollection 2021.
5
Impacts of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in alzheimer's disease.
BMC Med Genet. 2020 Sep 12;21(1):181. doi: 10.1186/s12881-020-01114-x.
6
Complement receptor 1 genetic polymorphism contributes to sporadic Alzheimer's disease susceptibility in Caucasians: a meta-analysis.
Biosci Rep. 2020 Jun 26;40(6). doi: 10.1042/BSR20200321.
7
Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer's Disease in a Prospective Cohort Study.
J Alzheimers Dis. 2020;75(2):417-427. doi: 10.3233/JAD-191335.
8
Evaluation of the Common Molecular Basis in Alzheimer's and Parkinson's Diseases.
Int J Mol Sci. 2019 Jul 30;20(15):3730. doi: 10.3390/ijms20153730.
9
Big Omics Data Experience.
SC Conf Proc. 2015 Nov;2015. doi: 10.1145/2807591.2807595.
10
The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease.
Sci Data. 2018 Sep 11;5:180185. doi: 10.1038/sdata.2018.185.
本文引用的文献
1
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.
Annu Rev Med. 2013;64:367-83. doi: 10.1146/annurev-med-092611-084441.
2
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.
Nature. 2013 Jan 31;493(7434):674-8. doi: 10.1038/nature11729. Epub 2012 Dec 19.
3
Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline.
Nat Med. 2012 Dec;18(12):1812-9. doi: 10.1038/nm.2965. Epub 2012 Nov 25.
4
Variant of TREM2 associated with the risk of Alzheimer's disease.
N Engl J Med. 2013 Jan 10;368(2):107-16. doi: 10.1056/NEJMoa1211103. Epub 2012 Nov 14.
5
Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype.
Biol Psychiatry. 2013 Mar 1;73(5):422-8. doi: 10.1016/j.biopsych.2012.08.015. Epub 2012 Sep 27.
6
C-reactive protein and familial risk for dementia: a phenotype for successful cognitive aging.
Neurology. 2012 Sep 11;79(11):1116-23. doi: 10.1212/WNL.0b013e3182698c89. Epub 2012 Aug 15.
7
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.
Neurology. 2012 Jul 17;79(3):229-36. doi: 10.1212/WNL.0b013e31825fdf18. Epub 2012 Jun 13.
8
Stitching together multiple data dimensions reveals interacting metabolomic and transcriptomic networks that modulate cell regulation.
PLoS Biol. 2012;10(4):e1001301. doi: 10.1371/journal.pbio.1001301. Epub 2012 Apr 3.
9
Distinguishing between longevity and buffered-deleterious genotypes for exceptional human longevity: the case of the MTP gene.
J Gerontol A Biol Sci Med Sci. 2012 Nov;67(11):1153-60. doi: 10.1093/gerona/gls103. Epub 2012 Apr 10.
10
A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort.
Genome Res. 2011 Jul;21(7):1008-16. doi: 10.1101/gr.112821.110. Epub 2011 May 20.
Zotero 插件